Vivesto Reports Approval of the US Clinical Paccal Vet Study in Dogs with Splenic Hemangiosarcoma
Shots:
- The US Veterinary Review Board Clinical Studies Committee has approved the company’s Paccal Vet clinical trial in dogs with splenic hemangiosarcoma following splenectomy
- The study will investigate Paccal Vet in dogs with various stages of splenic hemangiosarcoma (HSA) post-splenectomy. It comprises 4 treatment cycles and involves 2 cohorts, each with a maximum of 23 patients. Conducted at 6 clinical sites in Washington and Oregon, the first dosing is anticipated in early 2024, with a planned interim analysis in the H2’24
- Paccal Vet incorporates paclitaxel, formulated using the company's XR-17 technology
Ref: Vivesto | Image: Vivesto
Related News:- Jaguar Health’s Canalevia-CA1 Receives Conditional Approval Renewal from the US FDA for Chemotherapy-Induced Diarrhea in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
